Page 164 - 2022_03-Haematologica-web

R. Gurion et al.
11. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):e279-e282.
12. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910-941.
13. Dulery R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mor- tality after Covid-19 among patients with non-Hodgkin lymphoma treated with B- cell depleting immunotherapy. Am J Hematol. 2021;96(8):934-944.
14.Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
15. Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev. 2011(3):CD006505.
16.Auletta J, Chemaly R, Khawaja F, et al. General principles of COVID-19 vaccines for immunocompromised patients. Available at https://www.hematology.org/ covid-19/ash-astct-covid-19-and-vaccines. Last accessed in April 2021
17. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Available at https://www.cdc.gov/vaccines/covid- 19/info-by-product/clinical-considera- tions.html#underlying-conditions. Last
accessed in April 2021
18. He W, Chen L, Chen L, et al. COVID-19 in
persons with haematological cancers.
Leukemia. 2020;34(6):1637-1645.
19. Pleyer C, Ali MA, Cohen JI, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185-189. 20. Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin
Invest. 2020;130(12):6656-6667.
21. O'Nions J, Muir L, Zheng J, et al. SARS- CoV-2 antibody responses in patients with acute leukaemia. Leukemia. 2021;35(1):
289-292.
22.Sun C, Pleyer C, Wiestner A. COVID-19
vaccines for patients with haematological conditions. Lancet Haematol. 2021;8(5): e312-e314.
23.Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
24.Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005;3(4):214-220.
25.Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adju- vanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post- hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000.
Efficacy of the BNT162b2 mRNA COVID- 19 vaccine in patients with chronic lym- phocytic leukemia. Blood. 2021;137(23): 3165-3173.
27. Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2007;66(10):1402-1403.
28. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vacci- nation in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769-6771.
29.Tobinai K, Klein C, Oya N, Fingerle- Rowson G. A review of obinutuzumab (GA101), a novel type II anti-CD20 mono- clonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34(2):324-356.
30. Haberman AM, Gonzalez DG, Wong P, Zhang TT, Kerfoot SM. Germinal center B cell initiation, GC maturation, and the coevolution of its stromal cell niches. Immunol Rev. 2019;288(1):10-27.
31.Nguyen DC, Joyner CJ, Sanz I, Lee FE. Factors affecting early antibody secreting cell maturation into long-lived plasma cells. Front Immunol. 2019;10:2138.
32. Grupper A, Sharon N, Finn T, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing mainte- nance hemodialysis. Clin J Am Soc Nephrol. 2021;16(7):1037-1042.
26.
Herishanu Y, Avivi I, Aharon A, et al.
720
haematologica | 2022; 107(3)